To add precision to the nomenclature and nosology and remove stigma, experts are moving to rename nonalcoholic fatty liver disease as metabolic dysfunction-associated steatotic liver disease.
Andrew Cox, Pharm.D., MBA
Advertisement
Articles by Andrew Cox, Pharm.D., MBA
Based on the results published in the New England Journal of Medicine, the FDA has granted breakthrough status to the FGF21 analogue. The drug's maker is planning a phase 3 trial.
Advertisement
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
ALK Testing Strategies and Navigating First-Line Treatment Options in Advanced NSCLC
2
ALK-Positive NSCLC: Epidemiology, Prognosis, and the Critical Role of Biomarker Testing
3
How PBMs are tackling behavioral health
4
The women’s health conversation still has a migraine-sized gap
5